QT prolongation through hERG K+ channel blockade: Current knowledge and strategies for the early prediction during drug development

Medicinal Research Reviews

Volumn 25, Issue 2, 2005, Pages 133-166

  Recanatini, Maurizio ^a,b,c   Poluzzi, Elisabetta ^a   Masetti, Matteo ^a   Cavalli, Andrea ^a,d,e   De Ponti, Fabrizio ^a,f,g,h  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b Dept of Pharmaceutical Sciences ^*  (Italy)

^c POMONA COLLEGE   (United States)

^d SISSA   (Italy)

^e ETH ZURICH   (Switzerland)

^f UNIVERSITY OF PAVIA   (Italy)

^g MAYO CLINIC   (United States)

^h UNIVERSITY OF TURIN   (Italy)

Author keywords

3D QSAR; hERG K+ channels; QT prolongation; Safety pharmacology; Virtual screening

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; 1' (6 CYANO 1,2,3,4 TETRAHYDRO 2 NAPHTHYL) 3,4 DIHYDRO 6 METHANESULFONAMIDOSPIRO[2H 1 BENZOPYRAN 2,4' PIPERIDIN] 4 OL; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; BEPRIDIL; CISAPRIDE; CITALOPRAM; CLARITHROMYCIN; DESIPRAMINE; DOFETILIDE; DOMPERIDONE; DROPERIDOL; ENFLURANE; GATIFLOXACIN; GRANISETRON; HALOPERIDOL; ISOFLURANE; MACROLIDE; NEUROLEPTIC AGENT; OLANZAPINE; ONDANSETRON; PENTOBARBITAL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL HERG; QUETIAPINE; QUINIDINE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RISPERIDONE; SEVOFLURANE; SOTALOL; TACROLIMUS; UNINDEXED DRUG;

ANIMAL CELL; CARDIOTOXICITY; DISEASE MARKER; DRUG SCREENING; ELECTROCARDIOGRAM; HEART ARRHYTHMIA; HEART PROARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HUMAN CELL; LONG QT SYNDROME; NONHUMAN; QT PROLONGATION; REVIEW; SIDE EFFECT; SUDDEN DEATH; SYNCOPE; TORSADE DES POINTES;

ANIMALS; CATION TRANSPORT PROTEINS; ELECTROCARDIOGRAPHY; ETHER-A-GO-GO POTASSIUM CHANNELS; HUMANS; INHIBITORY CONCENTRATION 50; LONG QT SYNDROME; MODELS, BIOLOGICAL; MODELS, CHEMICAL; POTASSIUM; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; PROTEIN STRUCTURE, SECONDARY; STRUCTURE-ACTIVITY RELATIONSHIP; TIME FACTORS; TORSADES DE POINTES;

EID: 14544268139     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20019     Document Type: Review

References (168)

1. Zhang MQ. Chemistry underlying the cardiotoxicity of antihistamines. Curr Med Chem 1997;4:171-184.
2. Kitayama H, Kiuchi K, Nejima J, Katoh T, Takano T, Hayakawa H. Long-term treatment with antipsychotic drugs in conventional doses prolonged QTc dispersion, but did not increase ventricular tachyarrhythmias in patients with schizophrenia in the absence of cardiac disease. Eur J Clin Pharmacol 1999;55:259-262.
3. Malik M, Camm AJ. Evaluation of drug-induced QT interval prolongation: Implications for drug approval and labelling. Drug Saf 2001;24:323-351.
4. Yap YG, Camm AJ. Drug induced QT prolongation and torsades de pointes. Heart 2003;89:1363-1372.
5. Darpo B. Spectrum of drugs prolonging QT interval and the incidence of torsades de pointes. Eur Heart J Suppl 2001;3:K70-K80.
6. Viskin S. Long QT syndromes and torsade de pointes. Lancet 1999;354:1625-1633.
7. De Ponti F, Poluzzi E, Montanaro N, Ferguson J. QTc and psychotropic drugs. Lancet 2000;356:75-76.
8. De Ponti F, Poluzzi E, Montanaro N. Organising evidence on QT prolongation and occurrence of torsades de pointes with non-antiarrhythmic drugs: A call for consensus. Eur J Clin Pharmacol 2001;57:185-209.
9. + channel. J Pharmacol Exp Ther 2001;299:1007-1012.
10. Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W. Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: Fast phase 3 repolarization prevents early after depolarizations and torsade de pointes. J Pharmacol Exp Ther 2002;303:218-225.
11. + channel HERG. Mol Pharmacol 2001;59:122-126.
12. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S, Siegl PK, Strang I, Sullivan AT, Wallis R, Camm AJ, Hammond TG. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation, and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58:32-45.
13. European Agency for the Evaluation of Medicinal Products (EMEA). Committee for Proprietary Medicinal Products (CPMP): Points to consider: The assessment of the potential for QT interval prolongation by non-cardiovascular medicinal products. 1997.
14. European Agency for the Evaluation of Medicinal Products (EMEA). ICHS7B safety pharmacology studies for assessing the potential for delayed ventricular repolarisation (QT interval prolongation) by human pharmaceuticals. 2002.
15. Nattel S. The molecular and ionic specificity of antiarrhythmic drug actions. J Cardiovasc Electrophysiol 1999;10:272-282.
16. Towbin JA, Vatta M. Molecular biology and the prolonged QT syndromes. Am J Med 2001;110:385-398.
17. Sheridan DJ. Drug-induced proarrhythmic effects: Assessment of changes in QT interval. Br J Clin Pharmacol 2000;50:297-302.
18. Suessbrich H, Waldegger S, Lang F, Busch AE. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole. FEBS Lett 1996;385:77-80.
19. Suessbrich H, Schonherr R, Heinemann SH, Attali B, Lang F, Busch AE. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes. Br J Pharmacol 1997;120:968-974.
20. + channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol Pharmacol 1998;54:113-121.
21. Bischoff U, Schmidt C, Netzer R, Pongs O. Effects of fluoroquinolones on HERG currents. Eur J Pharmacol 2000;406:341-343.
22. Tie H, Walker BD, Valenzuela SM, Breit SN, Campbell TJ. The heart of psychotropic drug therapy. Lancet 2000;355:1825.
23. Cavero I, Mestre M, Guillon JM, Crumb W. Drugs that prolong QT interval as an unwanted effect: Assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000;1:947-973.
24. De Ponti F, Poluzzi E, Cavalli A, Recanatini M, Montanaro N. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsades de pointes: An overview. Drug Saf 2002;25:263-286.
25. De Ponti F, Poluzzi E, Montanaro N. QT-interval prolongation by non-cardiac drugs: Lessons to be learned from recent experience. Eur J Clin Pharmacol 2000;56:1-18.
26. Karagueuzian HS. Acquired long QT syndromes and the risk of proarrhythmia. J Cardiovasc Electrophysiol 2000;11:1298.
27. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-480.
28. Pond AL, Nerbonne JM. ERG proteins and functional cardiac I(Kr) channels in rat, mouse, and human heart. Trends Cardiovasc Med 2001;11:286-294.
29. + channel gating: Cloned delayed rectifier mechanisms and drug modulation. Can J Physiol Pharmacol 1998;76:77-89.
30. + channels: Friend and foe. Trends Pharmacol Sci 2001;22:240-246.
31. Shieh CC, Coghlan M, Sullivan JP, Gopalakrishnan M. Potassium channels: Molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 2000;52:557-594.
32. Tseng GN. I(Kr): The hERG channel. J Mol Cell Cardiol 2001;33:835-849.
33. Roden DM, George AL, Jr. Structure and function of cardiac sodium and potassium channels. Am J Physiol 1997;273:H511-H525.
34. Kennerdy A, Thomas P, Sheridan DJ. Generalized seizures as the presentation of flecainide toxicity. Eur Heart J 1989;10:950-954.
35. Platia EV, Estes M, Heine DL, Griffith LS, Garan H, Ruskin JN, Reid PR. Flecainide: Electrophysiologic and antiarrhythmic properties in refractory ventricular tachycardia. Am J Cardiol 1985;55:956-962.
36. Bruelle P, LeFrant JY, de La Coussaye JE, Peray PA, Desch G, Sassine A, Eledjam JJ. Comparative electrophysiologic and hemodynamic effects of several amide local anesthetic drugs in anesthetized dogs. Anesth Analg 1996;82:648-656.
37. O'Leary ME. Inhibition of human ether-à-go-go potassium channels by cocaine. Mol Pharmacol 2001;59:269-277.
38. Zhang S, Rajamani S, Chen Y, Gong Q, Rong Y, Zhou Z, Ruoho A, January CT. Cocaine blocks HERG, but not KvLQT1 + minK, potassium channels. Mol Pharmacol 2001;59:1069-1076.
39. Sesti F, Abbott GW, Wei J, Murray KT, Saksena S, Schwartz PJ, Priori SG, Roden DM, George AL, Jr., Goldstein SA. A common polymorphism associated with antibiotic-induced cardiac arrhythmia. Proc Natl Acad Sci USA 2000;97:10613-10618.
40. Gamouras GA, Monir G, Plunkitt K, Gursoy S, Dreifus LS. Cocaine abuse: Repolarization abnormalities and ventricular arrhythmias. Am J Med Sci 2000;320:9-12.
41. Parker RB, Perry GY, Horan LG, Flowers NC. Comparative effects of sodium bicarbonate and sodium chloride on reversing cocaine-induced changes in the electrocardiogram. J Cardiovasc Pharmacol 1999;34:864-869.
42. Wang RY. pH-dependent cocaine-induced cardiotoxicity. Am J Emerg Med 1999;17:364-369.
43. Papazian DM, Schwarz TL, Tempel BL, Jan YN, Jan LY. Cloning of genomic and complementary DNA from Shaker, a putative potassium channel gene from Drosophila. Science 1987;237:749-753.
44. + channels as therapeutic drug targets. Pharmacol Ther 2002;94:157-182.
45. Miller C. An overview of the potassium channel family. Genome Biol 2000;1:REVIEWS0004.
46. Choe S. Potassium channel structures. Nat Rev Neurosci 2002;3:115-121.
47. Ford JW, Stevens EB, Treherne JM, Packer J, Bushfield M. Potassium channels: Gene family, therapeutic relevance, high-throughput screening technologies, and drug discovery. Prog Drug Res 2002;58:133-168.
48. MacKinnon R. Potassium channels. FEBS Lett 2003;555:62-65.
49. Choe S, Kreusch A, Pfaffinger PJ. Towards the three-dimensional structure of voltage-gated potassium channels. Trends Biochem Sci 1999;24:345-349.
50. Yellen G. The voltage-gated potassium channels and their relatives. Nature 2002;419:35-42.
51. Gandhi CS, Isacoff EY. Molecular models of voltage sensing. J Gen Physiol 2002;120:455-463.
52. + conduction and selectivity. Science 1998;280:69-77.
53. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, MacKinnon R. Crystal structure and mechanism of a calcium-gated potassium channel. Nature 2002;417:515-522.
54. + channel. Nature 2003;423:33-41.
55. Kuo A, Gulbis JM, Antcliff JF, Rahman T, Lowe ED, Zimmer J, Cuthbertson J, Ashcroft FM, Ezaki T, Doyle DA. Crystal structure of the potassium channel KirBacl.1 in the closed state. Science 2003;300:1922-1926.
56. Lu Z, Klem AM, Ramu Y. Ion conduction pore is conserved among potassium channels. Nature 2001;413:809-813.
57. + channel. Nature 2003;423:42-48.
58. Cohen BE, Grabe M, Jan LY. Answers and questions from the KvAP structures. Neuron 2003;39:395-400.
59. Starace DM, Bezanilla F. A proton pore in a potassium channel voltage sensor reveals a focused electric field. Nature 2004;427:548-553.
60. Warmke JW, Ganetzky B. A family of potassium channel genes related to eag in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-3442.
61. Kr potassium channel. Cell 1995;81:299-307.
62. Tristani-Firouzi M, Sanguinetti MC. Structural determinants and biophysical properties of HERG and KCNQ1 channel gating. J Mol Cell Cardiol 2003;35:27-35.
63. + channels. J Biol Chem 2002;277:18994-19000.
64. Liu J, Zhang M, Jiang M, Tseng GN. Negative charges in the transmembrane domains of the HERG K channel are involved in the activation- and deactivation-gating processes. J Gen Physiol 2003;121:599-614.
65. Kr potassium channels with HERG and is associated with cardiac arrhythmia. Cell 1999;97:175-187.
66. + channel function in oocyte expression studies. J Biol Chem 2003;278:11739-11745.
67. Netzer R, Ebneth A, Bischoff U, Pongs O. Screening lead compounds for QT interval prolongation. Drug Discov Today 2001;6:78-84.
68. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: Clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J 2000;21:1216-1231.
69. Champeroux P, Martel E, Vannier C, Blanc V, Leguennec JY, Fowler J, Richard S. The preclinical assessment of the risk for QT interval prolongation. Therapie 2000;55:101-109.
70. Crumb W, Cavero II. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development. Pharm Sci Technol Today 1999;2:270-280.
71. Fenichel R. Drugs that alter ventricular repolarisation http://wwwfenichelnet/pages/Professional/subpages/QT/qthtm; 2003.
72. Davis AS. The pre-clinical assessment of QT interval prolongation: A comparison of in vitro and in vivo methods. Hum Exp Toxicol 1998;17:677-680.
73. Carlsson L. Drug-induced torsade de pointes: The perspectives of industry. Eur Heart J Suppl 2001;3:K114-K120.
74. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fiber: An in vitro model system for acquired long QT syndrome and drug-induced arrhythmogenesis. J Cardiovasc Pharmacol 2001;37:607-618.
75. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 1999;84:989-998.
76. Cavero I, Crumb W. Native and cloned ion channels from human heart: Laboratory models for evaluating the cardiac safety of new drugs. Eur Heart J Suppl 2001;3:K53-K63.
77. Lacerda AE, Kramer JK, Shen KZ, Thomas D, Brown AM. Comparison of block among cloned cardiac potassium channels by non-antiarrhythmic drugs. Eur Heart J Suppl 2001;3:K23-K30.
78. Rosen MR. Isolated tissue models and proarrhythmia. Eur Heart J Suppl 2001;3:K64-K69.
79. Escande D. Inhibition of repolarizing ionic currents by drugs. Eur Heart J Suppl 2001;3:K17-K22.
80. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001;103:2004-2013.
81. Hondeghem LM, Hoffmann P. Blinded test in isolated female rabbit heart reliably identifies action potential duration prolongation and proarrhythmic drugs: Importance of triangulation, reverse use dependence, and instability. J Cardiovasc Pharmacol 2003;41:14-24.
82. Hondeghem LM, Snyders DJ. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation 1990;81:686-690.
83. Weissenburger J, Nesterenko VV, Antzelevitch C. Transmural heterogeneity of ventricular repolarization under baseline and long QT conditions in the canine heart in vivo: Torsades de pointes develops with halothane but not pentobarbital anesthesia. J Cardiovasc Electrophysiol 2000;11:290-304.
84. Hammond TG, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Redfern WS, Sullivan AT, Camm AJ. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: Results of an international survey. Cardiovasc Res 2001;49:741-750.
85. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989;22:207-217.
86. Matsunaga T, Mitsui T, Harada T, Inokuma M, Murano H, Shibutani Y. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J Pharmacol Toxicol Methods 1997;38:201-209.
87. Spence S, Soper K, Hoe CM, Coleman J. The heart rate-corrected QT interval of conscious beagle dogs: A formula based on analysis of covariance. Toxicol Sci 1998;45:247-258.
88. Classen W, Altmann B, Gretener P, Souppart C, Skelton-Stroud P, Krinke G. Differential effects of orally versus parenterally administered qinghaosu derivative artemether in dogs. Exp Toxicol Pathol 1999;51:507-516.
89. Davis AS, Middleton BJ. Relationship between QT interval and heart rate in Alderley Park beagles. Vet Rec 1999;145:248-250.
90. Morganroth J. Focus on issues in measuring and interpreting changes in the QTc interval duration. Eur Heart J Suppl 2001;3:K105-K111.
91. Al Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003;289:2120-2127.
92. Paltoo B, O'Donoghue S, Mousavi MS. Levofloxacin induced polymorphic ventricular tachycardia with normal QT interval. Pacing Clin Electrophysiol 2001;24:895-897.
93. Moss AJ, Zareba W, Benhorin J, Couderc JP, Kennedy H, Locati-Heilbron E, Maison-Blanche P. ISHNE guidelines for electrocardiographic evaluation of drug-related QT prolongation and other alterations in ventricular repolarization: Task Force Summary A Report of the Task Force of the International Society for Holter and Noninvasive Electrocardiology (ISHNE), Committee on Ventricular Repolarization. Ann Noninvasive Electrocardiol 2001;6:333-341.
94. Malik M. Problems of heart rate correction in assessment of drug-induced QT interval prolongation. J Cardiovasc Electrophysiol 2001;12:411-420.
95. Bednar MM, Harrigan EP, Anziano RJ, Camm AJ, Ruskin JN. The QT interval. Prog Cardiovasc Dis 2001;43:1-45.
96. Wang Q, Bowles NE, Towbin JA. The molecular basis of long QT syndrome and prospects for therapy. Mol Med Today 1998;4:382-388.
97. Towbin JA, Wang Z, Li H. Genotype and severity of long QT syndrome. Drug Metab Dispos 2001;29:574-579.
98. Splawski I, Shen J, Timothy KW, Lehmann MH, Priori S, Robinson JL, Moss AJ, Schwartz PJ, Towbin JA, Vincent GM, Keating MT. Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A, KCNE1, and KCNE2. Circulation 2000;102:1178-1185.
99. + channel: Progress in understanding the molecular basis of its unusual gating kinetics. Eur Biophys J 2004;33:89-97.
100. Pinto YM, van Gelder IC, Heeringa M, Crijns HJ. QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999;353:980.
101. Scherer CR, Lerche C, Decher N, Dennis AT, Maier P, Ficker E, Busch AE, Wollnik B, Steinmeyer K. The antihistamine fexofenadine does not affect I(Kr) currents in a case report of drug-induced cardiac arrhythmia. Br J Pharmacol 2002;137:892-900.
102. Anantharam A, Markowitz SM, Abbott GW. Pharmacogenetic considerations in diseases of cardiac ion channels. J Pharmacol Exp Ther 2003;307:831-838.
103. Park KH, Kwok SM, Sharon C, Berga R, Sesti F. N-glycosylation-dependent block is a novel mechanism for drug-induced cardiac arrhythmia. FASEB J 2003;17:2308-2309.
104. Picker E, Obejero-Paz CA, Zhao S, Brown AM. The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (HERG) mutations. J Biol Chem 2002;277:4989-4998.
105. + channel long-QT2 mutations: Human ether-a-go-go-related gene rescue without block. Circulation 2002;105:2830-2835.
106. Kaufman ES, Ficker E. Is restoration of intracellular trafficking clinically feasible in the long QT syndrome: The example of HERG mutations. J Cardiovasc Electrophysiol 2003;14:320-322.
107. Schreiber SL. The small-molecule approach to biology. Chem Eng News 2003;81:51-61.
108. Mitcheson JS, Perry MD. Molecular determinants of high-affinity drug binding to HERG channels. Curr Opin Drug Discov Devel 2003;6:667-674.
109. + channels. Circ Res 1998;82:386-395.
110. Mitcheson JS. Drug binding to HERG channels: Evidence for a 'non-aromatic' binding site for fluvoxamine. Br J Pharmacol 2003;139:883-884.
111. Mitcheson JS, Chen J, Sanguinetti MC. Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J Gen Physiol 2000;115:229-240.
112. + channel structure-activity relationships and mechanisms of drug-induced QT prolongation. Annu Rev Pharmacol Toxicol 2003;43:441-461.
113. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000;97:12329-12333.
114. Chen J, Seebohm G, Sanguinetti MC. Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 2002;99:12461-12466.
115. + channel block. J Biol Chem 2002;277:23587-23595.
116. Sanchez-Chapula JA, Ferrer T, Navarro-Polanco RA, Sanguinetti MC. Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol Pharmacol 2003;63:1051-1058.
117. Fernandez D, Ghanta A, Kauffman GW, Sanguinetti MC. Physicochemical features of the HERG channel drug binding site. J Biol Chem 2004;279:10120- 10127.
118. Hammett LP. The effect of structure upon the reactions of organic compounds. Benzene derivatives. J Am Chem Soc 1937;59:96-103.
119. Hansch C, Fujita T. ρ-σ-π analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 1964;86:1616-1626.
120. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ. Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: Involvement of S6 sites. Mol Pharmacol 2000;57:367-374.
121. + channels by vesnarinone. Mol Pharmacol 2001;60:244-253.
122. Scholz EP, Zitron E, Kiesecker C, Lueck S, Kathofer S, Thomas D, Weretka S, Peth S, Kreye VA, Schoels W, Katus HA, Kiehn J, Karle CA. Drug binding to aromatic residues in the HERG channel pore cavity as possible explanation for acquired long QT syndrome by antiparkinsonian drug budipine. Naunyn Schmiedebergs Arch Pharmacol 2003;368:404-414.
123. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Blockade of HERG potassium currents by fluvoxamine: Incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 2003;139:887-898.
124. Milnes JT, Dempsey CE, Ridley JM, Crociani O, Arcangeli A, Hancox JC, Witchel HJ. Preferential closed channel blockade of HERG potassium currents by chemically synthesised BeKm-1 scorpion toxin. FEBS Lett 2003;547:20-26.
125. Diochot S, Loret E, Bruhn T, Beress L, Lazdunski M. APETx1: A new toxin from the sea anemone Anthopleura elegantissima, blocks voltage-gated human ether-a-go-go-related gene potassium channels. Mol Pharmacol 2003;64:59-69.
126. Kr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines. FASEB J 2003;17:2263-2265.
127. Ekins S. In silico approaches to predicting drug metabolism, toxicology and beyond. Biochem Soc Trans 2003;31:611-614.
128. van de Waterbeemd H, Gifford E. ADMET in silico modelling: Towards prediction paradise? Nat Rev Drug Discov 2003;2:192-204.
129. Morgan TK, Jr., Sullivan ME. An overview of Class III electrophysiological agents: A new generation of antiarrhythmic therapy. Prog Med Chem 1992;29:65-108.
130. Singh BN, Vaughan Williams EM. A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970;39:675-687.
131. + channel. Open-channel block by methanesulfonanilides. Circ Res 1996;78:499-503.
132. Segarra V, Lopez M, Ryder H, Palacios JM, Roberts DJ. Computer-assisted comparison of the structural and electronic dispositions of ebastine and terfenadine. Drug Saf 1999;21(Suppl 1):45-61; discussion 81-47.
133. Dewar MJS, Zoebisch EG, Healy EF, Stewart JPP. AM1: A new general purpose quantum mechanical molecular model. J Am Chem Soc 1985;107:3902-3909.
134. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985;28:849-857.
135. Ekins S, Crumb WJ, Sarazan RD, Wikel JH, Wrighton SA. Three-dimensional quantitative structure-activity relationship for inhibition of human ether-à-go-go-related gene potassium channel. J Pharmacol Exp Ther 2002;301:427-434.
136. + channel blockers. J Med Chem 2002;45:3844-3853.
137. Mohamadi F, Richards NGJ, Guida WC, Liskamp RMJ, Lipton MA, Caulfield CE, Chang G, Hendrickson TF, Still WC. MacroModel-An integrated software system for modeling organic and bioorganic molecules using molecular mechanics. J Comput Chem 1990;1:440-467.
138. + channels expressed in mammalian cell lines and Xenopus oocytes. J Pharmacol Toxicol Methods 2002;48:65-80.
139. Still WC, Tempzyk A, Hawley R, Hendrickson T. Semianalytical treatment of solvation for molecular mechanics and dynamics. J Am Chem Soc 1990;112:6127-6129.
140. Hansch C, Klein TE. Molecular graphics and QSAR in the study of enzyme-ligand interactions. On the definition of bioreceptors. Acc Chem Res 1986;19:392-400.
141. Recanatini M, Klein T, Yang CZ, McClarin J, Langridge R, Hansch C. Quantitative structure-activity relationships and molecular graphics in ligand receptor interactions: Amidine inhibition of trypsin. Mol Pharmacol 1986;29:436-446.
142. Recanatini M, Cavalli A, Belluti F, Piazzi L, Rampa A, Bisi A, Gobbi S, Valenti P, Andrisano V, Bartolini M, Cavrini V. Structure-activity relationships of 9-amino-1,2,3,4-tetrahydroacridine-based acetylcholinesterase inhibitors: Synthesis, enzyme inhibitory activity, QSAR, and structure-based CoMFA of tacrine analogues. J Med Chem 2000;43:2007-2018.
143. Cavalli A, Greco G, Novellino E, Recanatini M. Linking CoMFA and protein homology models of enzyme-inhibitor interactions: An application to non-steroidal aromatase inhibitors. Bioorg Med Chem 2000;8:2771-2780.
144. Pearlstein RA, Vaz RJ, Kang J, Chen XL, Preobrazhenskaya M, Shchekotikhin AE, Korolev AM, Lysenkova LN, Miroshnikova OV, Hendrix J, Rampe D. Characterization of HERG potassium channel inhibition using CoMSIA 3D QSAR and homology modeling approaches. Bioorg Med Chem Lett 2003;13:1829-1835.
145. Klebe G. Comparative molecular similarity indices: CoMSIA. In: Kubinyi H, Folkers G, Martin YC, editors. 3D QSAR in drug design. Great Britain: Kluwer Academic Publishers; 1998. Vol. 3. pp 87-104.
146. + channel. A model for bad behavior. J Med Chem 2003;46:2017-2022.
147. Roche O, Trube G, Zuegge J, Pflimlin P, Alanine A, Schneider G. A virtual screening method for prediction of the HERG potassium channel liability of compound libraries. Chembiochem 2002;3:455-459.
148. Keser GM. Prediction of hERG potassium channel affinity by traditional and hologram QSAR methods. Bioorg Med Chem Lett 2003;13:2773-2775.
149. Noble D. The rise of computational biology. Nat Rev Mol Cell Biol 2002;3:459-463.
150. Noble D. Modeling the heart-From genes to cells to the whole organ. Science 2002;295:1678-1682.
151. Noble D. Modelling the heart: Insights, failures, and progress. Bioessays 2002;24:1155-1163.
152. Muzikant AL, Penland RC. Models for profiling the potential QT prolongation risk of drugs. Curr Opin Drug Discov Dev 2002;5:127-135.
153. Mazhari R. "Are we there yet?" Cardiac channelopathy and our journey toward computational medicine. Circ Res 2002;90:842-843.
154. Levin JM, Penland RC, Stamps AT. Cho CR. Using in silico biology to facilitate drug development. Novartis Found Symp 2002;247:222-238; discussion 238-243, 244-252.
155. Selassie CD, Mekapati SB, Verma RP. QSAR: Then and now. Curr Top Med Chem 2002;2:1357-1379.
156. Hansch C, Hoekman D, Leo A, Weininger D, Selassie CD. Chem-bioinformatics: Comparative QSAR at the interface between chemistry and biology. Chem Rev 2002;102:783-812.
157. Akamatsu M. Current state and perspectives of 3D-QSAR. Curr Top Med Chem 2002;2:1381-1394.
158. Klebe G. Recent developments in structure-based drug design. J Mol Med 2000;78:269-281.
159. Sotriffer C, Klebe G. Identification and mapping of small-molecule binding sites in proteins: Computational tools for structure-based drug design. Farmaco 2002;57:243-251.
160. 3H]Dofetilide binding to HERG transfected membranes: A potential high throughput preclinical screen. Eur J Pharmacol 2001;430:147-148.
161. Eckardt L, Haverkamp W, Borggrefe M, Breithardt G. Experimental models of torsade de pointes. Cardiovasc Res 1998;39:178-193.
162. + channel opener to reduce transmural dispersion of repolarization and prevent torsade de pointes in LQT1, LQT2, and LQT3 models of the long-QT syndrome. Circulation 2000;102:706-712.
163. Yang T, Snyders D, Roden DM. Drug block of Ikr: Model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-744.
164. Lu HR, Remeysen P, Somers K, Saels A, De Clerck F. Female gender is a risk factor for drug-induced long QT and cardiac arrhythmias in an in vivo rabbit model. J Cardiovasc Electrophysiol 2001;12:538-545.
165. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 1999;100:2455-2461.
166. Yamamoto K, Tamura T, Imai R, Yamamoto M. Acute canine model for drug-induced torsades de pointes in drug safety evaluation-influences of anesthesia and validation with quinidine and astemizole. Toxicol Sci 2001;60:165-176.
167. Van Opstal JM, Leunissen JD, Wellens HJ, Vos MA. Azimilide and dofetilide produce similar electrophysiological and proarrhythmic effects in a canine model of torsade de pointes arrhythmias. Eur J Pharmacol 2001;412:67-76.
168. Ishii K, Kondo K, Takahashi M, Kimura M, Endoh M. An amino acid residue whose change by mutation affects drug binding to the HERG channel. FEBS Lett 2001;506:191-195.